Press Releases

Press Releases

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


IVI Conducts Cholera Vaccination Campaign in Earthquake-hit Nepal

2016-10-07 07:15

  • More than 10,000 Nepalese people were vaccinated against cholera with funds donated from Kim & Chang and Yanghyun Foundation

  • “IVI will continue its efforts on protecting people in developing countries from cholera and other infectious diseases,” said IVI Director General Dr. Jerome Kim

SEOUL, KOREA – The International Vaccine Institute (IVI), an international organization based in Seoul, announced on September 1 the successful rollout of a cholera vaccination campaign, immunizing more than 10,000 people, including children above the age of one, in remote areas devastated by the earthquakes that struck Nepal earlier this year.

The mass vaccination campaign was conducted to protect communities at risk for cholera, a highly contagious and potentially fatal diarrheal disease. Many people are living under difficult conditions with limited access to clean water, sanitation and health care services as a result of the severe damage caused by the two earthquakes in April and May. In addition, the heavy rain associated with monsoon season, which runs from June to October, exacerbates the risk for cholera.

In partnership with the Epidemiology and Disease Control Division (EDCD) & District Health Office (DHO), Nuwakot & Dhading under  the Ministry of Health & Population, Government of Nepal; UNICEF Country Office Nepal; WHO Country Office Nepal; Group for Technical Assistance (GTA), Nepal and Rotary Club of Nagarjuna, Nepal, IVI coordinated the implementation of the vaccination campaign in several wards of Nuwakot and Dhading districts, rural, remote places that are hard to reach. The oral cholera vaccine (Shanchol™), which was developed by IVI and approved by WHO, is given in two doses.  The first dosing ran from August 8 to 12 and the second dosing has been in process from August 30 to September 3.

The cholera vaccination campaign was made possible due to funds donated by Kim & Chang, one of Korea’s largest law firms. As part of its CSR programs, executives and staff members at Kim & Chang have made contributions to IVI through, among others, an annual in-house fundraising event in collaboration with the Korea Support Committee for IVI over the past five years. Kim & Chang supported the vaccination to protect victims of the earthquakes in Nepal, a country with endemic cholera, which has had frequent seasonal outbreaks around the monsoon season. In the wake of the earthquakes that devastated the health infrastructure, people in the affected areas are at high risk of potential cholera outbreaks.

“Thanks to generous support from our donors such as Kim & Chang, we were able to immunize more than 10,000 people in Nepal against deadly cholera,” said IVI Director General Dr. Jerome Kim. “Since the earthquakes damaged the health infrastructure in parts of the country, it is likely that more vaccinations will be needed to protect vulnerable people in high-risk environments, and IVI anticipates more organizations in Korea to extend support for additional vaccinations.”

“It is a great privilege for Kim & Chang to support IVI’s endeavors to protect earthquake victims from cholera in Nepal,” said Mr. Mok Young-joon, Chairman of the Kim & Chang CSR Committee. “Wishing for Nepal’s recovery from the earthquake, Kim & Chang will continue to work with IVI to save and improve the lives of children in developing countries including Nepal.”

Meanwhile, Yanghyun Foundation also made a donation to IVI in early August to support the cholera vaccination campaign in Nepal.


About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to discovering, developing and delivering new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research at its headquarters in Seoul, Republic of Korea and in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, as well as dengue fever. For more information, please visit

Media Contacts:

Public Awareness/Advocacy Officer, IVI

Tae-kyung Byun

+82 2 872 2801 (Ext. 159) / Mobile +82 11 9773 6071


Burson-Marsteller Korea Contact:

Ayoung Jang

Phone: +82-2-3782-6465

Mobile: +82-10-3596-2440




Nayoung Kim

Phone: +82-2-3782-6458

Mobile: +82-10-8967-1909